The China Oncology Pipeline Is Going Global — And Pfizer Just Fired the Starting Gun
Pfizer's deal with Innovent Biologics joins a pattern of Western pharma betting on Chinese oncology pipelines to fill post-LOE...
HER2 Oncology
BioNTech’s Endometrial ADC Data Is Not a Science Story — It’s a $3 Billion Market Access Problem in Disguise
Trastuzumab pamirtecan just posted compelling Phase 2 numbers in HER2-expressing recurrent endometrial cancer. The science is clean. The commercial...